Pagina 1 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
Curriculum Vitae
Europass
Personal Information
Surname(s) / Name(s) PASELLO GIULIA
TAX CODE
Nationality
PSLGLI79R57L407G
Italian
Date of birdth 17/10/1979
Gender
Tel
Email:
Female
+390498215608
Occupational Field Medical Oncology
Work experience
Dates
Occupation or position held
Main activities and responsabilities
Name and address of employer
Type of business or sector
Dates
07/01/2014-current position
Associate Medical Director
Clinical and research activity in thoracic oncology
Second Medical Oncology Unit, Istituto Oncologico
Veneto, Via Gattamelata 64, 35128 Padua (Italy)
Medical Oncology
01/02/2010- 06/01/2014
Occupation or position held Medical Oncologist (with contract)
Main activities and responsabilities Clinical and research activity in thoracic oncology
Name and address of employer Second Medical Oncology Unit, Istituto Oncologico
Veneto, Via Gattamelata 64, 35128 Padua (Italy)
Type of business or sector Medical oncology
Dates 01/07/2009 - 01/12/2009
Pagina 2 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
Occupation or position held Fellow
Main activities and responsabilities Basic research about malignant pleural mesothelioma
Name and address of employer Molecular Oncology laboratories, University of Zurich
(Switzerland), Prof. Rolf Stahel
Type of business or sector Molecular Oncology
Dates 01/07/2008 - 31/12/2008
Occupation or position held Resident in Medical Oncology
Main activities and responsabilities Clinical management of oncological pediatric patients
Name and address of employer Pediatric oncohematology, University of Padua (Italy)
Type of business or sector Pediatric Oncology and Haematology
Dates 01/07/2007 - 31/12/2009
Occupation or position held Resident in Medical Oncology
Main activities and responsabilities Clinical management and research in Oncology
Name and address of employer Second Medical Oncology Unit, Istituto Oncologico
Veneto
Padua (Italy)
Type of business or sector Medical Oncology
Dates 01/01/2006 - 30/06/2007
Occupation or position held Resident in Medical Oncology
Main activities and responsabilities Basic and translational research in oncology
Name and address of employer Oncological and Surgical Science Department, Oncology
Section, University of Padua (Italy)
Type of business or sector Molecular Oncology
Education and Training
Dates 01/01/2012-31/12/2014
Title of qualification awarded PhD
Principal subjects/occupational
skills covered
Neoangiogenic biomarkers and therapeutic targets in
malignant pleural mesothelioma
Pagina 3 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
Dates 01/01/2006 - 31/12/2010
Title of qualification awarded Residency in Medical Oncology
Principal subjects/occupational
skills covered
Medical Oncology
Name and type of organisation
providing education and training
University of Padua (Italy)
Dates 01/10/1999 - 11/10/2005
Title of qualification awarded Graduation in medicine and surgery
Name and type of organisation
providing education and training
Number of medical register subscription
Other training experiences
University of Ferrara (Ferrara, Italy)
TV04727
March 2014: admitted at the 13th ESO ESMO Masterclass
in Clinical Oncology where she attended plenary lectures
regarding state-of-the-art clinical evaluation and
treatments in oncology. As a selected participant the
applicant presented a research abstract which was
selected for publication and had the opportunity to
present and discuss with the faculty clinical cases of
thoracic cancer.
Personal skills and competences
Mother tongue(s) Italian
Other language(s) English: excellent reading, writing, speaking
Organisational skills and
competences
Experience in clinical trial partecipation according to
GCP rules:
-Participation as Co-Investigator to about 40 clinical trials
in the field of thoracic oncology;
- Principal Investigator of about 15 clinical trials in the
Pagina 4 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
Awards and Grants
field of thoracic oncology (Lung Cancer, Malignant
Pleural Mesothelioma, Thymic malignancies).
-Clinical and translational research projects design and
conduction.
- 2015: recipient of My First AIRC Grant for the
translational project “MET-targeting in Small Cell
Lung Cancer)
- 2014 ‘Saro Leggio’ award of the Associazione Italiana
Ricerca Patologie Polmonari (AIRPP) for translational
study of malignant pleural mesothelioma
- 2012: recipient of IMIG (International Mesothelioma
Interest group) travel award
- 2010-2011: recipient of ESMO (European Society for
Medical Oncology) translational research fellowship
award for the project “Identification of novel molecular
targets and biological agents for the chemotherapy of
Malignant Pleural Mesothelioma”
List of publications:
IF: 200,596 (06 nov 2018)
H INDEX : 10 (06 nov 2018)
Citations: 326 (06 nov 2018)
FULL PAPER PUBLICATIONS IN PEER REVIEWED
JOURNALS WITH IMPACT FACTOR
1) Pasello G, Agata S, Bonaldi L, Corradin A,
Montagna M, Zamarchi R, Parenti A, Cagol M, Zaninotto
G, Ruol A, Ancona E, Amadori A and Saggioro D.“DNA
copy number alterations correlate with survival of
oesophageal adenocarcinoma patients”. Modern
Patology, 2009;22 (1):58-65.
IF: 5.485
Pagina 5 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
2) Favaretto A, Pasello G, Magro C, Schettino C, Gridelli
C. “Second and third line treatment in non-small-cell
lung cancer”. Crit Rev Oncol Hematol, 2009; 71 (2):117-
126
IF: 5.039
3) Favaretto A, Pasello G, Loreggian L, Breda C, Braccioni
F, Marulli G, Stragliotto S, Magro C, Sotti G, Rea F.
“Preoperative concomitant chemo-radiotherapy (CT-RT)
in Superior Sulcus Tumor (SST): a mono-institutional
experience”. Lung Cancer, 2010 May; 68(2):228-33
IF: 3.767
4) Pasello G and Favaretto A. “Molecular targets in
malignant pleural mesotelioma treatment”. Current Drug
Targets, 2009; 10: 1235-1244.
IF: 3.029
5) Sidi R*, Pasello G*, Opitz I, Soltermann A, Tutic M,
Rehrauer H, Weder W, Stahel RA, Felley-Bosco E. *Equal
contributors “Induction of senescence markers after neo-
adjuvant chemotherapy of malignant pleural
mesothelioma and association with clinical outcome: An
exploratory analysis”. Eur J Cancer, 2011; 47 (2): 326-32.
IF: 6.163
6) Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi
L, Galligioni A, Indraccolo S, Pasello G, Rea F and
Favaretto A. “Prognostic and Predictive Implications of
EGFR mutations, EGFR copy number and KRAS mutations
in advanced stage lung adenocarcinoma”. Anticancer
Research 2010; 30: 5121-5128
IF: 1.895
7) Gridelli C, Morgillo F, Favaretto A, de Marinis F, Chella
A, Cerea G, Mattioli R, Tortora G, Rossi A, Fasano M,
Pasello G, Ricciardi S, Maione P, Di Maio M &
Ciardiello F. “Sorafenib in combination with erlotinib or
Pagina 6 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
with gemcitabine in elderly patients with advanced non-
small-cell lung cancer: a randomized phase II study”
Annals of Oncology, 2011; 22 (7): 1528-34
11.855
8) Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli
P, Magro C, Jirillo A, Favaretto A. “Platinum-based
doublet chemotherapy in pre-treated malignant pleural
mesothelioma (MPM) patients: A mono-institutional
experience” Lung Cancer, 2011;73: 351-355
IF: 3.767
9) Rumiato E, Pasello G, Montagna M, Scaini MC, De
Salvo GL, Parenti A, Cagol M, Ruol A, Ancona E, Amadori
A, Saggioro D. “DNA copy number profile discriminates
between esophageal adenocarcinoma and squamous cell
carcinoma and represents an independent prognostic
parameter in esophageal adenocarcinoma”. Cancer
Letters, 2011; 310 (1): 84-9
IF: 5.992
10) Gridelli C, Gallo C, Morabito A, Iaffaioli RV, Favaretto
A, Isa L, Barbera S, Gamucci T, Ceribelli A, Filipazzi V,
Maione P, Rossi A, Barletta E, Signoriello S, De Maio E,
Piccirillo MC, Di Maio M, Rocco G, Vecchione A, Perrone
F; G-STEP Investigators “Phase I-II trial of gemcitabine-
based first-line chemotherapies for small cell lung cancer
in elderly patients with performance status 0-2: the G-
STEP trial” J Thorac Oncol. 2012 Jan;7(1):233-42
IF: 5.040
11) Pasello G, Ceresoli GL, Favaretto A “An overview of
neoadjuvant chemotherapy in the multimodality
treatment of malignant pleural mesotelioma”. Cancer
Treat Rev. 2013 Feb;39 (1):10-7
IF: 7.983
12) Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F,
Pagina 7 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R,
Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi
F, Spatafora M, Ravaioli A, Felletti R, Fregoni V,
Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito
A, Tsao MS, Signoriello S, Perrone F, Gridelli C; TORCH
Investigators. “Quality of life analysis of TORCH, a
randomized trial testing first-line erlotinib followed by
second-line cisplatin/gemcitabine chemotherapy in
advanced non-small-cell lung cancer.” J Thorac Oncol.
2012 Dec;7 (12):1830-4
IF: 5.040
13) Pasello G, Marulli G, Polo V, Breda C, Bonanno L,
Loreggian L, Rea F, Favaretto A. “Pemetrexed plus
carboplatin or cisplatin as neoadjuvant treatment of
operable malignant pleural mesothelioma (MPM)”
Anticancer Res. 2012 Dec;32 (12):5393-9.
IF: 1.895
14) Marulli G, Di Chiara F, Braccioni F, Perissinotto E,
Pasello G, Gino Favaretto A, Breda C, Rea F. “Changes in
pulmonary function tests predict radiological response to
chemotherapy in malignant pleural mesothelioma” Eur J
Cardiothorac Surg. 2013 Jul; 44 (1):104-10
IF: 2.803
15) Pasello G, Urso L, Conte P, Favaretto A. “Effects of
Sulfonylureas on Tumor Growth: A Review of the
Literature”. The Oncologist 2013, 18(10):1118-1125
IF: 4.789
16) Ceresoli GL, Grosso F, Zucali PA, Mencoboni M,
Pasello G, Ripa C, Degiovanni D, Simonelli M, Bruzzone
A, Dipietrantonj C, Piccolini E, Beretta GD, Favaretto AG,
Giordano L, Santoro A, Botta M. “Prognostic factors in
elderly patients with malignant pleural mesothelioma:
results of a multicenter survey.” Br J Cancer. 2014 Jul
Pagina 8 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
15;111(2):220-6.
IF: 5.569
17) Marulli G, Verderi E, Zuin A, Schiavon M, Battistella L,
Perissinotto E, Romanello P, Favaretto AG, Pasello G, Rea
F. “Outcomes and prognostic factors of non-small-cell
lung cancer with lymph node involvement treated with
induction treatment and surgical resection.”
Interact Cardiovasc Thorac Surg. 2014 Aug;19(2):256-62
IF: 1.329
18) Pasello G, Urso L, Silic-Benussi M, Schiavon M,
Cavallari I, Marulli G, Nannini N, Rea F, Ciminale V,
Favaretto A. “Synergistic antitumor activity of
recombinant human Apo2L/TRAIL in combination with
Carboplatin and Pemetrexed in Malignant Pleural
Mesothelioma”. J Thorac Oncol 2014, 2014 Jul;9(7):1008-
17
IF: 5.040
19) Schiavon M, Marulli G, Nannini N, Pasello G, Lunardi
F, Balestro E, Perissinotto E, Rebusso A, Saetta M, Rea F,
Calabrese F. “COPD-related adenocarcinoma presents
low aggressiveness morphological and molecular
features compared to smoker tumours”. Lung Cancer.
2014 Dec;86(3):311-7.
IF: 3.767
20) Marulli G, Battistella L, Perissinotto E, Breda C,
Favaretto AG, Pasello G, Zuin A, Loreggian L, Schiavon M,
Rea F.”Results of surgical resection after induction
chemoradiation for Pancoast tumours †.”
Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):805-11
IF: 1.329
21) Pasello G, Carli P, Canova F, Bonanno L, Polo V, Zago
G, Urso L, Conte P, Favaretto A. “Epirubicin plus
paclitaxel regimen as second-line treatment of patients
Pagina 9 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
with small-cell lung cancer.” Anticancer Res. 2015
Apr;35(4):2183-9.
IF: 1.895
22) Urso L, Calabrese F, Favaretto A, Conte PF and
Pasello G. “Critical review about MDM2 in cancer:
possible role in malignant mesothelioma and
implications for treatment” Critical Review in Oncology
and Hematology 2016 Jan;97:220-30
IF: 5.039
23) Pasello G, Urso L, Mencoboni M, Grosso F, Ceresoli GL,
Lunardi F, Vuljan SE, Bertorelle R, Sacchetto V, Ciminale V,
Rea F, Favaretto A, Conte PF, Calabrese F. “MDM2 and
HIF1alpha expression levels in different histologic
subtypes of Malignant Pleural Mesothelioma: correlation
with pathological and clinical data.” Oncotarget, 2015 Dec
8;6(39):42053-66
IF: 5.008
24) Ferrazzi A, Russo I, Pasello G, Alaibac M. “Atypical skin
reaction in a patient treated with gefitinib for advanced
lung cancer: A case report and review of the literature”.
Exp Ther Med. 2016 Jan;11(1):197-200
IF: 1.56
25) Polo V, Pasello G, Frega S, Favaretto A, Koussis H,
Conte P, Bonanno L.” Squamous cell carcinomas of the
lung and of the head and neck: new insights on molecular
characterization.” Oncotarget. 2016 May 3;7(18):25050-
63
IF: 5.008
26) Frega S, Conte P, Fassan M, Polo V, Pasello G. A Triple
Rare E709K and L833V/H835L EGFR Mutation Responsive
to an Irreversible Pan-HER Inhibitor: A Case Report of
Lung Adenocarcinoma Treated with Afatinib.
J Thorac Oncol. 2016 May;11(5):e63-4
Pagina 10 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
IF: 5.040
27) Bonanno L, Zago G, Marulli G, Del Bianco P, Schiavon
M, Pasello G, Polo V, Canova F, Tonetto F, Loreggian L,
Rea F, Conte P, Favaretto A. “Radiological response and
survival in locally advanced non-small-cell lung cancer
patients treated with three-drug induction chemotherapy
followed by radical local treatment.”
Onco Targets Ther. 2016 Jun 21;9:3671-81
IF: 2.311
28) Valentina Polo, Giulia Pasello. “Multimodality
treatment in limited small cell lung cancer (L-SCLC):
different perspectives about the optimal approach” .
Transl Cancer Res Vol 5, Supplement 2 (August 2016):
IF: 1.757
29) Russo I, Sacco G, Frega S, Polo V, Pasello G, Alaibac
M. “Immunotherapy-related skin toxicity: bullous
pemphigoid in a lung adenocarcinoma patient treated
with the anti-PDL1 antibody atezolizumab.” Eur J
Dermatol. 2017 Mar 1. doi: 10.1684/ejd.2016.2959.
IF: 2.069
30) Stefano Frega, Martina Lorenzi, Matteo Fassan,
Stefano Indraccolo, Fiorella Calabrese, Adolfo Favaretto,
Laura Bonanno, Valentina Polo, Giulia Zago, Francesca
Lunardi, Ilaria Attili, Alberto Pavan, Massimo Rugge,
Valentina Guarneri, PierFranco Conte, Giulia Pasello6.
“Clinical features and treatment outcome of non-small
cell lung cancer (NSCLC) patients with uncommon or
complex epidermal growth factor receptor (EGFR)
mutations” Oncotarget March 2017 DOI:
10.18632/oncotarget.15945
IF: 5.008
31) Mencoboni M, Filiberti RA, Taveggia P, Grosso F,
Pasello G, Del Corso L, Muzio A, Polo V, Zucali P, Ceresoli
Pagina 11 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
GL, Soto Parra HJ, Auriati L, Simonassi C. “Clinical
Features and Treatment Outcome of Malignant Pleural
Mesothelioma.”
Oncol Res Treat. 2017;40(6):364-369.
IF: 1.333
32) Urso L, Cavallari I, Silic-Benussi M, Biasini L, Zago G,
Calabrese F, Conte PF, Ciminale V, Pasello G. “Synergistic
targeting of malignant pleural mesothelioma cells by
MDM2 inhibitors and TRAIL agonists.”
Oncotarget. 2017 May 11.
IF: 5.008
33) Gobbini E, Pilotto S, Pasello G, Polo V, Di Maio M,
Arizio F, Galetta D, Petrillo P, Chiari R, Matocci R, Di
Costanzo A, Di Stefano TS, Aglietta M, Cagnazzo C,
Sperduti I, Bria E, Novello S. “Effect of Contract Research
Organization Bureaucracy in Clinical Trial Management:
A Model From Lung Cancer.”
Clin Lung Cancer. 2017 Oct 28. pii: S1525-
7304(17)30306-6.
IF: 3.434
34) Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A,
Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F,
Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M,
Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L,
Bertossi M, Destro A, Di Tommaso L, Santoro A. “Phase II
Study of Everolimus in Patients With Thymoma and Thymic
Carcinoma Previously Treated With Cisplatin-Based
Chemotherapy.”
J Clin Oncol. 2017 Dec 14:JCO2017744078
IF: 24.008
35) Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G,
Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto
F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F,
Pagina 12 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
Additional information
Calabrese F. “Malignant pleural mesothelioma immune
microenvironment and checkpoint expression: correlation
with clinical-pathological features and intra-tumor
heterogeneity over time.” Ann Oncol. 2018 Mar 5. doi:
10.1093/annonc/mdy086
IF: 11.855
36) Frega S, Bonanno L, Guarneri V, Conte P, Pasello G.
Therapeutic perspectives for brain metastases in non-
oncogene addicted non-small cell lung cancer (NSCLC):
Towards a less dismal future? Crit Rev Oncol Hematol.
2018 Aug;128:19-29.
IF:5.039
37) Imbimbo M, Vitali M, Fabbri A, Ottaviano M, Pasello G,
Petrini I, Palmieri G, Berardi R, Zucali P, Ganzinelli M,
Marabese M, Broggini M, Marino M, Trama A, Rulli E,
Hollander L, Pruneri G, Torri V, Garassino MC. RELEVENT
Trial: Phase II Trial of Ramucirumab, Carboplatin, and
Paclitaxel in Previously Untreated Thymic Carcinoma/B3
Thymoma With Area of Carcinoma.
Clin Lung Cancer. 2018 Jul 3. pii: S1525-7304(18)30164-5
IF: 3.434
38) Bonanno L, Pavan A, Dieci MV, Di Liso E, Schiavon M,
Comacchio G, Attili I, Pasello G, Calabrese F, Rea F,
Favaretto A, Rugge M, Guarneri V, Fassan M, Conte PF
The role of immune microenvironment in small-cell lung
cancer: Distribution of PD-L1 expression and prognostic
role of FOXP3-positive tumour infiltrating lymphocytes.
Eur J Cancer. 2018 Aug 1;101:191-200. doi:
10.1016/j.ejca.2018.06.023. [Epub ahead of print]
IF: 7.191
39) Pelosi G, Papotti M, Righi L, Rossi G, Ferrero S, Bosari S,
Calabrese F, Kern I, Maisonneuve P, Sonzogni A, Albini A,
Harari S, Barbieri F, Capelletto E, Catino AM, Cavone D, De
Pagina 13 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
Palma A, Fusco N, Lunardi F, Maiorano E, Marzullo A,
Novello S, Papanikolaou N, Pasello G, Pennella A, Pezzuto
F, Punzi A, Prisciandaro E, Rea F, Rosso L, Scattone A, Serio
G. Pathologic Grading of Malignant Pleural Mesothelioma:
An Evidence-Based Proposal.
J Thorac Oncol. 2018 Nov;13(11):1750-1761
IF: 5.040
40) Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G,
Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M,
Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R,
Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L,
Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-
Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA.
Best practices for the management of thymic epithelial
tumors: A position paper by the Italian collaborative group
for ThYmic MalignanciEs (TYME). Cancer Treat Rev. 2018
Oct 5;71:76-87.
IF: 7.983
41) Pasello G, Vicario G, Zustovich F, Oniga F, Gori S,
Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo
A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C,
Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M,
Menis J, Corte DD, Frega S, Guarneri V, Conte P; Veneto
Oncology Network From Diagnostic-Therapeutic Pathways
to Real-World Data: A Multicenter Prospective Study on
Upfront Treatment for EGFR-Positive Non-Small Cell Lung
Cancer (MOST Study). Oncologist. 2019 Mar 7.
IF
42. Comacchio GM, Schiavon M, Azzolina D, Mammana
M, Marulli G, Zuin A, Verderi E, Monaci N, Bonanno
L, Pasello G, Rea F. Does Induction Therapy Increase
Anastomotic Complications in Bronchial Sleeve
Resections? World J Surg. 2019 Jan 18.
Pagina 14 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
43. Bonanno L, Pavan A, Attili I, Pasello G, Guarneri V.
Immunotherapy in SCLC: Exceptional Clinical Benefit and
Abscopal Pneumonitis After Radiotherapy.
J Thorac Oncol. 2019 Jan;14(1):e5-e7.
FULL PAPER PUBLICATIONS IN PEER REVIEWED
JOURNALS WITHOUT IMPACT FACTOR
1) Favaretto AG, Pasello G, and Magro C
“Second and third line treatment in advanced non-small
cell lung cancer”. Discovery Medicine, 2009; 8 (43): 204-
209.
2) Pasello G, Altavilla G, Bonanno L, Rea F, Favaretto A.
“A pathological complete response after preoperative
chemotherapy with carboplatin and pemetrexed in
malignant pleural mesothelioma: a case report”. J Thorac
Disease 2010; 2: 254-257.
3) Polo V, Zago G, Frega S, Canova F, Bonanno L,
Favaretto A, Bonaldi L, Bertorelle R, Conte PF, Pasello G.
“Non-Small Cell Lung Cancer in a Very Young Woman: A
Case Report and Critical Review of the Literature”
American Journal of Case Reports, Nov 3;16:782-9
BOOK CHAPTER
- Giulia Pasello and Adolfo Favaretto. Neoadjuvant
Chemotherapy in Malignant Pleural Mesothelioma.
Malignant Mesothelioma Chapter 5 December 2012.
http://dx.doi.org/10.5772/47880
- Giovanni Luca Ceresoli, Giulia Pasello, Fiorella
Calabrese. ESMO book: Thoracic Tumours –Essentials
for Clinicians: Malignant Pleural Mesothelioma
March 2014
- OncologiaEdizione italiana a cura di Vittorina
Zagonel DE VITA - HELLMANN - LAWRENCE –
Pagina 15 / 15 - Curriculum vitae di PASELLO GIULIA
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010
ROSENBERG (Piccin)
- Participation as a speaker and scientiific
committee to several national and international
conferences
- 2011- 2014 National AIOM (Associazione Italiana
di Oncologia Medica) young working group elected
member
- Reviewer of several peer reviewer journals
focused on thoracic oncology
- Member of ASCO since 2008; member of ESMO
and AIOM since 2009; member of IASLC since 2018
I authorize the handling of my personal data according to
Italian data protection Law.
PADOVA, 25/mar/2019